FDA Conditionally Approves Eli Lilly's Thyroid Cancer Drug For Pediatric Patients With Certain Mutations
Wednesday, the FDA granted accelerated approval to Eli Lilly And Co’s LLY selpercatinib (Retevmo) for pediatric patients two years of age and older with the following: Advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, who require …